Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923128 | 1.00 | BRD4 (0.33) | BRD4CREBBPKDM4CMAPK1WNT3A | |
| SCHEMBL30782890 | 0.89 | KDM4C (0.33) | KDM4CUCHL1HTR2CSLC6A4 | |
| SCHEMBL27214623 | 0.89 | KDM4C (0.33) | KDM4CUCHL1HTR2CSLC6A4 | |
| SCHEMBL30782853 | 0.89 | KDM4C (0.33) | KDM4CUCHL1HTR2CSLC6A4 | |
| SCHEMBL30782850 | 0.89 | KDM4C (0.33) | KDM4CUCHL1HTR2CSLC6A4 | |
| SCHEMBL29923280 | 0.89 | KDM4C (0.33) | KDM4CUCHL1HTR2CSLC6A4 | |
| SCHEMBL27214590 | 0.88 | BRD4 (0.34) | BRD4CREBBPKDM4CHTR2CSLC6A4 | |
| SCHEMBL27214554 | 0.88 | BRD4 (0.34) | BRD4CREBBPKDM4CHTR2CSLC6A4 | |
| SCHEMBL27231219 | 0.88 | BRD4 (0.34) | BRD4CREBBPKDM4CHTR2CSLC6A4 | |
| SCHEMBL29923158 | 0.88 | SCN9A (0.34) | BRD4CREBBPKDM4CCNR2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | TAAR1, HTR1A, HTR1F | BRD4 931/4885CREBBP 800/4885KDM4C 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.